Trial · NCT00153166

ARREST PAD (Peripheral Arterial Disease)

NCT00153166, Phase 2, Phase 3, Completed, Brigham and Women's Hospital; results first posted 2014-09-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. ARREST PAD (Peripheral Arterial Disease). Trials, record NCT00153166. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00153166

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: ARREST PAD (Peripheral Arterial Disease)
NCT number: NCT00153166
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 76 participants, actual
Lead sponsor: Brigham and Women's Hospital
Conditions: Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
Interventions: atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo
First posted: 2005-09-12
Last updated: 2014-09-30
Results first posted: 2014-09-30

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Lower Extremity Skeletal Muscle Glucose Uptake	60 minutes	Net calf skeletal muscle glucose uptake determined by Patlak modeling.
Secondary	'M' = Whole Body Insulin Sensitivity	every 5 minutes for 20 minutes	A hyperinsulinemic-euglycemic clamp was performed prior to and during FDG-PET imaging to measure insulin sensitivity and to standardize metabolic conditions. Subjects were required to fast for 8 hours prior to the study. Patients were given a primed insulin infusion of 2 mU/kg/min. Serum glucose measurements were made at five-minute intervals from an arterialized venous sample achieved by placing the hand in a warming box at 50°C. Blood glucose levels are checked every 5 minutes and 20% dextrose infusion is adjusted to maintain a serum glucose level of approximately 80 mg/dL. Subjects were considered to have achieved steady state when the dextrose infusion rate required to maintain a serum glucose level of 80 mg/dL varied by no greater than 5%. To compute the steady-state glucose disposal rate, we averaged the glucose infusion rates over the last 20 minutes of the clamp and applied a "space correction" to account for small changes in serum glucose levels over that time period.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Lower Extremity Skeletal Muscle Glucose Uptake	60 minutes	Baseline Characteristics were collected according to the clinical diagnosis of the patients and not according to randomization. Participants were grouped at Baseline and are presented here irrespective of randomization because the primary intention was to compare the different types of patients regardless of interventions received.	umol/kg/min	MEAN
SECONDARY	'M' = Whole Body Insulin Sensitivity	every 5 minutes for 20 minutes	Baseline Characteristics were collected according to the clinical diagnosis of the patients and not according to randomization. Participants were grouped at Baseline and are presented here irrespective of randomization because the primary intention was to compare the different types of patients regardless of interventions received.	mg/kg/min	MEDIAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Lower Extremity Skeletal Muscle Glucose Uptake	Healthy Controls	62.9	Standard Deviation 21	umol/kg/min
Lower Extremity Skeletal Muscle Glucose Uptake	Patients With PAD	48.6	Standard Deviation 15	umol/kg/min
Lower Extremity Skeletal Muscle Glucose Uptake	PAD (Excluding Diabetes)	49.5	Standard Deviation 3.1	umol/kg/min
'M' = Whole Body Insulin Sensitivity	Healthy Controls	5.0	Inter-Quartile Range 3.7 to 6.6	mg/kg/min
'M' = Whole Body Insulin Sensitivity	Patients With PAD	3.4	Inter-Quartile Range 2.7 to 4.8	mg/kg/min
'M' = Whole Body Insulin Sensitivity	PAD (Excluding Diabetes)	3.4	Inter-Quartile Range 2.8 to 4.9	mg/kg/min

Source ClinicalTrials.gov

Participant flow21

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Healthy Controls	11
Overall Study	STARTED	Patients With PAD	37
Overall Study	STARTED	PAD (Excluding Patients With Diabetes)	28
Overall Study	Received Atorvastatin and Pioglitazone	Healthy Controls	3
Overall Study	Received Atorvastatin and Pioglitazone	Patients With PAD	9
Overall Study	Received Atorvastatin and Pioglitazone	PAD (Excluding Patients With Diabetes)	7
Overall Study	Received Atorvastatin and Placebo	Healthy Controls	2
Overall Study	Received Atorvastatin and Placebo	Patients With PAD	9
Overall Study	Received Atorvastatin and Placebo	PAD (Excluding Patients With Diabetes)	7
Overall Study	Received Placebo and Pioglitazone	Healthy Controls	3

1 to 10 of 21Source ClinicalTrials.gov

See all 21 participant flow

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Received Atorvastatin/Pioglitazone
Total, all-cause mortality	Received Atorvastatin/Placebo
Total, all-cause mortality	Received Placebo/Pioglitazone
Total, all-cause mortality	Received Placebo/Placebo
Total, other adverse events	Received Atorvastatin/Pioglitazone	0	19
Total, other adverse events	Received Atorvastatin/Placebo	0	18
Total, other adverse events	Received Placebo/Pioglitazone	0	20
Total, other adverse events	Received Placebo/Placebo	0	19
Total, serious adverse events	Received Atorvastatin/Pioglitazone	0	19
Total, serious adverse events	Received Atorvastatin/Placebo	0	18

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
25095746	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01HL075771	Inflammation and Insulin Resistance in PAD	CREAGER, MARK A	BRIGHAM AND WOMEN'S HOSPITAL	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2003 to 2007

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00153166

GET https://conductscience.org/api/trials/v1/NCT00153166/flow?page=2

API reference For AI assistants